乳腺癌辅助放疗大分割方案比较:3周标准方案与1周新方案的多中心随机III期试验方案
该研究为印度多中心开放标签随机III期试验,旨在验证1周5次放疗方案在5年局部区域复发率上非劣效于3周15次标准方案,计划入组2100例需辅助放疗的乳腺癌患者,主要终点为5年局部区域复发率,非劣效界值3%。
要点
- 对照组为40 Gy/15次/3周,试验组为26 Gy/5次/1周,保乳患者允许同步整合推量8 Gy和6 Gy。
- 样本量2100例提供80%把握度检测5年局部区域复发率3%的非劣效性,单侧I类错误2.5%。
- 若1周方案非劣效,将提高放疗可及性并降低成本,同时标准化全国放疗质控。
核心结论
- 假设1周5次放疗方案在5年局部区域复发率上非劣效于3周15次标准方案。
研究设计与样本
- 多中心、开放标签、随机对照III期试验,在印度大型学术中心招募无远处转移且需辅助放疗的乳腺癌患者。
- 计划样本量2100例,招募期5年,随后随访5年。
主要发现
- 原文未报告试验结果,仅描述设计。
关键数值与推荐
- 对照组:全乳或胸壁(伴/不伴区域淋巴结)40 Gy/15次/3周;试验组:同体积26 Gy/5次/1周。
- 保乳患者允许同步整合推量,两组剂量分别为8 Gy和6 Gy。
- 非劣效界值:5年局部区域复发率差异3%,假设对照组5年局部区域复发率为5%(对应风险比1.63),单侧I类错误2.5%,把握度80%。
临床怎么用
- 若试验证实1周方案非劣效,可缩短放疗疗程至1周,提高放疗可及性并降低治疗成本。
- 试验同步进行全国放疗实践标准化和质量保证。
局限性
- 研究人群为非高加索人群且包含更多需乳房切除和瘤床推量的晚期患者,结果外推需谨慎。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypofractionated radiotherapy is the current standard for adjuvant radiotherapy across many centres. Further hypofractionation may be possible but remains to be investigated in non-Caucasian populations with more advanced disease, with a higher proportion of patients requiring mastectomy as well as tumour bed boost. We are reporting the design of randomized controlled trial testing the hypothesis that a 1-week (5 fractions) regimen of radiotherapy will be non-inferior to a standard 3-week (15 fractions) schedule. METHODS: We describe a multicentre, randomized controlled trial recruiting patients at large academic centres across India. Patients without distant metastases who merit adjuvant radiotherapy will be eligible for inclusion in the study. Patients in the control arm will receive adjuvant radiotherapy to the breast or chest wall (with/without regional nodes) to a dose of 40 Gy/15 fractions/3 weeks, while those in the experimental arm will receive a dose of 26 Gy/5 fractions/1 week (to the same volume). The use of a simultaneous integrated boost (dose of 8 Gy and 6 Gy, respectively) is allowed in patients who have undergone breast conservation. A sample size of 2100 patients provides an 80% power to detect a non-inferiority of 3% in the 5-year locoregional recurrence rate with a one-sided type I error of 2.5%, assuming that the locoregional recurrence rate in the control arm is 5% at 5 years (corresponding to a hazard ratio of 1.63). Patients will be recruited over a period of 5 years and followed up for a further 5 years thereafter. DISCUSSION: If a five-fraction regimen of breast cancer is proven to be non-inferior, this will result in a significant improvement in the access to radiotherapy, as well as reduced costs of treatment. The trial gives an opportunity to standardize and quality-assure radiotherapy practices across the nation at the same time. Along with the results of the FAST-Forward trial, the safety of this intervention in advanced node-positive disease requiring regional nodal radiation will be established. TRIAL REGISTRATION: The trial has been registered at the Clinical Trial Registry of India (CTRI) vide registration number: CTRI/2018/12/016816 (December 31, 2018) as well as the ClinicalTrial.gov website at NCT03788213 (December 28, 2018).
引用
- Chatterjee S, Chakraborty S. Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)-study protocol for a multicentre, randomized phase III trial. Trials. 2020. PMID: 32998747. doi:10.1186/s13063-020-04751-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。